影响安罗替尼对晚期非小细胞肺癌临床疗效的多因素分析  

Multivariate analysis of the clinical efficacy of anlotinib in treatment of advanced non-small cell lung cancer

作　　者：沈旦[1] 陈澄[1] 朱晔[2] 曾大雄[1] 黄建安[1] 石建[2] SHEN Dan;CHEN Cheng;ZHU Ye;ZENG Da-xiong;HUANG Jian-an;SHI Jian(Department of Pulmonary and Critical Care Medicine,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China;Department of Pharmacy,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China)

机构地区：[1]苏州大学附属第一医院呼吸与危重症医学科,江苏苏州215006 [2]苏州大学附属第一医院药学部,江苏苏州215006

出　　处：《临床肺科杂志》2022年第10期1543-1547,共5页Journal of Clinical Pulmonary Medicine

基　　金：江苏省药学会-奥赛康医院药学基金项目(No.A201911);苏州科技计划项目(No.SYS2020098)。

摘　　要：目的探索影响安罗替尼治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)临床疗效的因素。方法收集2019年1月1日至2021年4月30日于苏州大学附属第一医院呼吸与危重症医学科使用安罗替尼治疗的晚期NSCLC患者的临床资料,记录患者安罗替尼治疗的疾病控制率(disease control rate,DCR)及无进展生存期(progression free survival,PFS),计算DCR及PFS,并分析其影响因素。结果总共105例患者被纳入研究,所有患者的DCR为81.0%,其中单药使用安罗替尼的DCR为56.8%,安罗替尼联合治疗的DCR为94.1%。Logistic回归提示:联合用药为提高DCR的独立保护因素,体力状态(performance status,PS)评分2分以上、心包转移为DCR的独立危险因素。使用安罗替尼的所有患者,中位PFS时间为12.2月。PS评分0~1分、联合用药的患者,中位PFS时间高于PS评分2分以上、单药使用的患者,有统计学差异。结论安罗替尼对晚期NSCLC具有较好的DCR,影响安罗替尼DCR的因素包括心包转移、患者PS评分和联合用药;影响安罗替尼PFS时间的因素为患者PS评分和联合用药。安罗替尼是临床治疗肺癌的一种非常有潜力的药物。Objective To explore the factors influencing the clinical efficacy of anlotinib in treatment of advanced non-small cell lung cancer.Methods The clinical data of advanced NSCLC patients treated with anlotinib were collected.The disease control rate(DCR)and progression free survival(PFS)were recorded,and the influencing factors of DCR and PFS were calculated.Results A total of 105 patients were enrolled.The DCR of all patients was 81.0%,including 56.8%of patients treated with single agent and 94.1%of patients treated with combined agents.PS score above 2 and pericardial metastasis were independent risk factors for DCR.The median PFS of all patients was 12.2 months.The cox proportional hazards model analysis indicated that PS score and combination of drugs affected the PFS of patients treated with anlotinib.The median PFS time of patients with PS score 0~1 was higher than that of patients with PS score more than 2.The median duration of PFS was longer in patients treated with combination therapy than in patients treated with single therapy.Conclusion Anlotinib has a good disease control rate for NSCLC.The factors influencing the DCR of anlotinib include pericardial metastasis,PS score and combination therapy.The factors influencing the PFS of anlotinib are PS score and combination therapy.Anlotinib is a potential drug for clinical treatment of NSCLC.

关 键 词：非小细胞肺癌 安罗替尼 抗血管生成治疗 

分 类 号：R734.2[医药卫生—肿瘤]